Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade.

ABSTRACT:

Background

Although the second-generation androgen receptor inhibitors and taxanes have recently been recommended for the initial treatment of metastatic prostate cancer, bicalutamide and flutamide are still used in a large number of cases. Therefore, it is important to elucidate the clinical characteristics of these treated CRPC cases and their sensitivity to the currently used therapeutic agents. We aimed to examine the outcomes of metastatic castration-resistant prostate cancer following combined androgen blockade as initial therapy at our institution.

Methods

Ninety-four patients who developed metastatic castration-resistant prostate cancer after hormonal treatment with combined nonsteroidal androgen receptor antagonists and continuous androgen deprivation therapy betwee

SUBMITTER: Obinata D 

PROVIDER: S-EPMC10148407 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature